The nuclear pore complex (NPC) is a massive protein assembly (~125 MDa in humans) that serves as the sole gateway for molecular transport between the cytoplasm and nucleus["@nuclear2000"]. Composed of multiple nucleoporin proteins arranged in eight-fold symmetry, the NPC regulates bidirectional movement of macromolecules while maintaining the integrity of the nuclear envelope. Emerging evidence demonstrates that NPC dysfunction is a critical pathological mechanism in multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington's disease (HD), and Alzheimer's disease (AD)[@nuclear2022]. The disruption of nucleocytoplasmic transport represents an emerging frontier in understanding the molecular basis of neurodegeneration, with implications for biomarker development and therapeutic intervention.
The human NPC consists of approximately 30 distinct nucleoporin (NUP) proteins, each present in multiple copies (8-32 copies per NPC) for a total of roughly 500 polypeptide subunits[@nuclear2017]. The core scaffold is formed by the inner ring complex (NUP53, NUP54, NUP58, NUP62, NUP58), which anchors the complex within the nuclear envelope. Cytoplasmic filaments (NUP358/RanBP2, NUP214) extend into the cytoplasm and function in mRNA export and docking of import/export receptors. Nuclear basket filaments (NUP153, NUP50) project into the nucleoplasm and participate in receptor recycling and gene regulation[@nuclear2017a].
The central channel contains phenylalanine-glycine (FG)-repeat nucleoporins (NUP62, NUP58, NUP54, NUP52) that form a selective hydrogel barrier[@nuclear2020]. Transport receptors including importin-α/β, exportin-1 (CRM1), and NXF1/TAP bind to cargo proteins and interact with FG repeats through hydrophobic interactions, enabling facilitated diffusion while blocking inert molecules larger than ~40 kDa. This sophisticated architecture enables the selective transport of proteins, RNAs, and ribonucleoprotein complexes while maintaining the nuclear envelope as a physical barrier[@nuclear2019].
A defining feature of NPC pathology in neurodegeneration is the abnormal aggregation and degradation of specific nucleoporins. In ALS and FTD, [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology is strongly associated with mislocalization and degradation of multiple nucleoporins, particularly NUP62, NUP58, and NUP54 in the spinal cord and motor [cortex](/brain-regions/cortex)[@nup2020]. The sequestration of nucleoporins into TDP-43 positive inclusions depletes functional NPC components, creating "leaky" nuclear envelopes with compromised permeability barriers. This loss of barrier function allows inappropriate passage of molecules between nucleus and cytoplasm, disrupting cellular homeostasis[@tdp2019].
NUP358/RanBP2, a large cytoplasmic filament nucleoporin, forms characteristic inclusions in a subset of ALS cases with orbiculin pathology[@nup2019]. These NUP358 inclusions colocalize with ubiquitin and p62, suggesting impaired proteostasis at the nuclear envelope. The formation of these inclusions represents a specific pathological signature that may inform disease classification and understanding of pathogenesis.
Nuclear transport receptors (NTRs) including importin-α, importin-β, and CRM1 exhibit altered expression, localization, and function in neurodegenerative diseases. In ALS/FTD, exportin CRM1 shows relocalization from the nuclear envelope to cytoplasmic aggregates, accompanied by impaired nuclear export of mRNAs and proteins[@crm2020]. This mislocalization of transport receptors represents a critical bottleneck in cellular logistics, affecting thousands of nuclear-cytoplasmic communication pathways.
The Ran GTPase system, which powers directional transport through the NPC, demonstrates disrupted nucleocytoplasmic Ran gradients in models of TDP-43 proteinopathy[@ran2018]. This gradient disruption further compromises the efficiency of both import and export processes, creating a feedforward cycle of transport deficiency. The bidirectional nature of this dysfunction amplifies cellular stress and contributes to progressive neuronal dysfunction.
The nuclear export of mRNA is a critical function of the NPC that becomes severely impaired in neurodegeneration. NXF1/TAP, the primary mRNA export receptor, and its cofactor NXT/p15 show reduced expression and mislocalization in ALS motor [neurons](/entities/neurons)[@mrna2022]. This results in nuclear accumulation of polyadenylated mRNA, disrupting post-transcriptional gene regulation and contributing to transcriptional homeostasis failure. The accumulation of unspliced or improperly processed mRNAs in the nucleus triggers additional cellular stress responses[@nuclear2023].
In Huntington's disease, mutant [huntingtin protein](/proteins/huntingtin) directly interacts with NPC components including NUP62 and NUP153, impairing both mRNA export and protein import[@mutant2019]. The selective vulnerability of medium spiny neurons in HD may relate to their particularly high nucleocytoplasmic transport demands. This cell-type-specific vulnerability provides insight into disease-specific patterns of neurodegeneration.
ALS and FTD represent a disease spectrum with shared molecular mechanisms, including TDP-43 proteinopathy. Nuclear pore dysfunction is particularly prominent in this spectrum. Post-mortem studies reveal severe loss of NUP62 in motor neurons of sporadic ALS cases, with residual NUP62 sequestered into TDP-43 inclusions[@nup2020a]. The formation of NUP358 (RanBP2) immunopositive inclusions occurs in approximately 10% of ALS cases, representing a distinct pathological subtype[@nup2019a]. Electron microscopy demonstrates membrane ruffling and NPC disorganization in affected neurons, providing structural evidence of nuclear envelope pathology[@nuclear2020a].
Genetic links strengthen the connection between NPC dysfunction and ALS/FTD. Mutations in genes encoding nucleoporins and transport factors (NUP50, NUP62, NUP88) have been identified in rare familial ALS cases[@als2023]. Additionally, hexanucleotide repeat expansions in [C9orf72](/entities/c9orf72), the most common genetic cause of ALS/FTD, generate dipeptide repeat proteins that localize to the nuclear envelope and impair nucleocytoplasmic transport[@corf2015]. This genetic evidence confirms that NPC dysfunction is not merely a consequence of neurodegeneration but may represent a primary disease mechanism.
Nuclear pore alterations in AD are less characterized but emerging evidence indicates involvement. NUP98, a nucleoporin linked to gene regulation and transport, shows altered expression in AD brain tissue[@nup2021]. The nuclear envelope demonstrates increased permeability in AD models, correlating with cognitive decline[@nuclear2020b]. Age-related disruption of nuclear pore integrity may accelerate amyloid and [tau](/proteins/tau) pathology through impaired clearance mechanisms, creating a vicious cycle of cellular dysfunction.
NPC dysfunction is a well-established mechanism in HD. Mutant huntingtin directly binds to NUP62 and NUP153, disrupting their normal function[@huntingtinnpc2019]. Nuclear pore permeability increases in HD models and patient tissue, with quantified changes in transport kinetics demonstrating functional significance[@nuclear2018]. Gene expression studies reveal downregulation of multiple nucleoporin genes in HD striatum, suggesting transcriptional regulation of NPC components as part of disease pathogenesis[@nucleoporin2016].
The relationship between NPC dysfunction and RNA-binding protein pathology is bidirectional. TDP-43, which forms the hallmark inclusions in ALS/FTD, normally localizes to the nucleus where it regulates splicing and mRNA stability[@tdp2022]. Loss of nuclear TDP-43 function due to cytoplasmic mislocalization contributes to nucleoporin downregulation and transport defects. This creates a pathogenic loop where transport dysfunction leads to further protein mislocalization.
FUS (fused in sarcoma) protein, mutated in familial ALS, similarly affects NPC function. FUS binds to mRNA export factors and its pathological aggregation disrupts mRNA export[@fus2020]. The shared involvement of multiple RNA-binding proteins in NPC dysfunction suggests a common pathway in neurodegeneration.
The NPC interfaces with both the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) and [autophagy](/entities/autophagy). NUPs tagged with ubiquitin are subject to proteasomal degradation, and the NPC itself can be targeted for autophagic clearance when damaged[@npc2020]. Impaired proteostasis in neurodegeneration thus contributes to NPC degradation, while NPC dysfunction impairs the nuclear import of transcription factors required for proteostasis gene expression.
The nuclear pore facilitates DNA repair factor access to damaged chromatin. NPC dysfunction may therefore exacerbate DNA damage accumulation in neurons, which have limited replicative capacity but high metabolic demands[@npc2022]. This connection between NPC dysfunction and DNA damage may contribute to the genomic instability observed in neurodegenerative diseases.
NPC pathology represents a potential biomarker target. Cerebrospinal fluid nucleoporin levels are being investigated as biomarkers, with NUP62 fragments detectable in CSF of ALS patients, suggesting neuronal NPC breakdown[@csf2022]. PET ligands targeting the nuclear envelope are under development for detecting NPC dysfunction in vivo. Genetic screening for nucleoporin gene variants may serve as risk modifiers in neurodegenerative diseases.
The nuclear transport machinery offers several therapeutic targets. Small molecule transport modulators including importin inhibitors and CRM1 blockers are in development for ALS/FTD[@targeting2021]. Gene therapy approaches using viral delivery of wildtype nucleoporins to restore NPC function represent a promising avenue. Small molecules stabilizing NPC by enhancing nucleoporin expression or preventing degradation are actively being investigated.
Compounds that enhance proteasome and autophagy function may indirectly stabilize the NPC. Autophagy inducers such as rapamycin and related compounds promote clearance of damaged NPC components. Novel small molecules enhancing proteasome function may prevent nucleoporin accumulation.
Preventing TDP-43 and FUS aggregation could preserve NPC integrity. Antisense oligonucleotides targeting TDP-43 expression are in clinical trials for ALS[@aso2023]. Small molecule aggregation inhibitors targeting the RRM domain are under development and may provide disease-modifying benefits.
Several key questions remain. What initiates NPC dysfunction in sporadic neurodegeneration? Why are specific neuronal populations (motor neurons, striatal neurons) more vulnerable to NPC pathology? Can nucleoporin fragments serve as early diagnostic markers? At what disease stage might NPC-targeted interventions be most effective? Addressing these questions will require continued basic science investigation and translational development of biomarkers and therapeutics.
Recent advances in nuclear pore complex dysfunction: